Type 1 Diabetes

This episode includes a breakdown of topline data from ATTAIN-1 and part 1 of the recap for ADCES 2025.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

Isaacs, Bellini, and Levy discuss a currently recruiting trial investigating CGM metrics in pregnant individuals with type 1 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Shah discusses the results from the ADJUST-T1D trial comparing semaglutide to placebo, which saw a significant disparity in semaglutide’s favor.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.

Donovan and Feig shared exciting findings and further research from a study evaluating an insulin pump with Control-IQ technology with Dexcom G6 sensor.

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Adult-onset T1D significantly raises cardiovascular disease and mortality risks, highlighting the need for improved management and prevention strategies.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.

In this episode, experts discuss practical guidance for screening for presymptomatic type 1 diabetes with Rifka Schulman-Rosenbaum, MD.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

In the first of 2 episodes spotlighting the meeting, hosts break down news and updates from the Advanced Technologies and Treatments for Diabetes meeting.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.